

# Blueteq is not just about cost, it's an opportunity to optimise antiretroviral therapy.

Sinéad Peare, Stephanie Tyler, Dr Ranjababu Kulasegaram  
Guys and St Thomas' NHS Foundation Trust




## BACKGROUND

In February 2022 NHS England and Improvement changed the way it purchases Antiretrovirals (ARVs) to a national procurement agreement allowing equal access to ARVs across the country.<sup>[1]</sup> Symtuza, Rezolsta, Evotaz and Eviplera no longer became routinely recommended and decisions to continue were to be through a multi-disciplinary team meeting and Blueteq submission.

## METHODS

Patients on Symtuza, Rezolsta, Evotaz and Eviplera were identified from the Trust's dispensing platform and upon clinical review, data was collated surrounding the switch and reasons for patients remaining on existing treatment. Data was then collated, cost of therapies added and analysed to calculate cost savings.

## RESULTS



## CONCLUSIONS

- £45,000 per month has been saved through switching therapies. However 27% of patients switched to more expensive regimens.
- Blueteq has prompted switches away from regimens containing boosted PIs in 57% of patients who switched treatment.
- Single tablet regimens and adherence along with patient preference were the main reason for treatment choices.
- 61% of patients remained on current regimens but 76% of patients remained on Symtuza
- Blueteqs have been used as an opportunity to discuss ARVs with patients and ensure they continue to take the medication that best suits their needs.